IN2012DN02487A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02487A
IN2012DN02487A IN2487DEN2012A IN2012DN02487A IN 2012DN02487 A IN2012DN02487 A IN 2012DN02487A IN 2487DEN2012 A IN2487DEN2012 A IN 2487DEN2012A IN 2012DN02487 A IN2012DN02487 A IN 2012DN02487A
Authority
IN
India
Prior art keywords
enantiomers
esters
useful
formula
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
David Joseph Bartkovits
Xin-Jie Chu
Jin-Jun Liu
Tina Morgan Ross
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN02487A publication Critical patent/IN2012DN02487A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN2487DEN2012 2009-10-14 2010-10-11 IN2012DN02487A (pm)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25141309P 2009-10-14 2009-10-14
US34562610P 2010-05-18 2010-05-18
PCT/EP2010/065159 WO2011045257A1 (en) 2009-10-14 2010-10-11 Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions

Publications (1)

Publication Number Publication Date
IN2012DN02487A true IN2012DN02487A (pm) 2015-08-28

Family

ID=43567698

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2487DEN2012 IN2012DN02487A (pm) 2009-10-14 2010-10-11

Country Status (12)

Country Link
US (1) US8017607B2 (pm)
EP (1) EP2488491A1 (pm)
JP (1) JP2013507416A (pm)
KR (1) KR20120081210A (pm)
CN (1) CN102548963A (pm)
AU (1) AU2010305914A1 (pm)
BR (1) BR112012008485A2 (pm)
CA (1) CA2774512A1 (pm)
IL (1) IL218018A0 (pm)
IN (1) IN2012DN02487A (pm)
MX (1) MX2012003982A (pm)
WO (1) WO2011045257A1 (pm)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
PT2603600T (pt) 2010-08-13 2019-02-27 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2012076513A1 (en) * 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
DK2684880T3 (en) 2011-03-10 2018-05-22 Daiichi Sankyo Co Ltd DISPIROPYRROLIDINE DERIVATIVES
WO2013059525A1 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
AU2013221433B2 (en) 2012-02-15 2018-01-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104159595A (zh) 2012-02-15 2014-11-19 爱勒让治疗公司 拟肽大环化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス,インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
CN112972378A (zh) 2014-09-24 2021-06-18 艾瑞朗医疗公司 拟肽大环化合物及其制剂
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック, インコーポレイテッド Protac抗体コンジュゲート及び使用方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
EP1202994B1 (en) 1999-07-21 2004-04-14 AstraZeneca AB New compounds
WO2005099687A2 (en) 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7423051B2 (en) 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 2,6-diaminopyridine derivatives
WO2006091646A2 (en) 2005-02-22 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
CA2636824A1 (en) 2006-01-18 2007-07-26 F. Hoffmann-La Roche Ag Cis-4,5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors
MX2009000285A (es) 2006-06-30 2009-06-08 Schering Corp Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2010031713A1 (en) * 2008-09-18 2010-03-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides

Also Published As

Publication number Publication date
CA2774512A1 (en) 2011-04-21
AU2010305914A1 (en) 2012-03-08
US8017607B2 (en) 2011-09-13
JP2013507416A (ja) 2013-03-04
KR20120081210A (ko) 2012-07-18
US20110086854A1 (en) 2011-04-14
MX2012003982A (es) 2012-05-08
WO2011045257A1 (en) 2011-04-21
CN102548963A (zh) 2012-07-04
IL218018A0 (en) 2012-04-30
EP2488491A1 (en) 2012-08-22
BR112012008485A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
IN2012DN02487A (pm)
MY165238A (en) Substituted pyrrolidine-2-carboxamides
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
MY160596A (en) Spiroindolinone pyrrolidines
TW200801000A (en) Spiroindolinone derivatives
IL205354A0 (en) Spiroindolinone derivatives
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
IL193620A0 (en) Spiroindolinone derivatives
IL205506A0 (en) Spiroindolinone derivatives as anticancer agents
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2012008141A (es) Compuestos y metodos.
IL208025A0 (en) Spiroindolinone derivatives
MX2011007886A (es) Derivado de espiroindolinona piridina.
WO2014062838A3 (en) Pkm2 modulators and methods for their use
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MY178583A (en) Hydantoin derivative
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
MX2012005155A (es) Compuestos de quinazolina.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
IN2013CN00515A (pm)
MX2013013021A (es) Nuevos compuestos de hexahidropirroloimidazolona.
MX2010008778A (es) Derivados de 3-alquil-piperazina y usos de la misma.